REG - Roquefort Theraptcs. - Director/PDMR Shareholding

Roquefort TherapeuticsAnnouncement

04/02/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250204:nRSD8629Va&default-theme=true

RNS Number : 8629V  Roquefort Therapeutics PLC  04 February 2025

4 February 2025

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Director/PDMR Shareholding

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on developing first in class medicines in the high value and high
growth immunology and oncology markets, advises that Stephen West, Executive
Chairman and Ajan Reginald, CEO have purchased ordinary shares of £0.01 each
in the Company ("Ordinary Shares"), as detailed below:

 

 Director       Number of Ordinary Shares Acquired  Average Price Paid per Share  Total Consideration Paid  Number of Ordinary Shares Now Held  % of Company's Issued Capital
 Stephen West*  400,000                             2.57 pence                    £10,338.85                6,710,853                           4.9%
 Ajan Reginald  191,059                             2.60 pence                    £5,000.00                 12,537,472                          9.2%

 

*4,628,485 of Mr West's Ordinary Shares are held in the name of Cresthaven
Investments Pty Ltd ATF the Bellini Trust.

-ENDS-

Enquiries:
 Roquefort Therapeutics plc                      +44 (0)20 3918 8633
 Stephen West (Chairman) / Ajan Reginald (CEO)
 SP Angel Corporate Finance LLP (Broker)         +44 (0) 20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Burson Buchanan (Public Relations)              +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper / George Beale
 Peak IR (Investor Relations)                    +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing first in class drugs in the high value and high growth immunology
and oncology markets prior to partnering with big pharma.

 

Roquefort Therapeutics' portfolio consists of five novel patent-protected
pre-clinical anti-cancer medicines.  The highly complementary profile of five
best-in-class medicines consists of:

 

·    Midkine antibodies with significant in vivo efficacy and toxicology
studies;

·    Midkine RNA therapeutics with novel anti-cancer gene editing action;

·    Midkine mRNA therapeutics with novel anti-cancer approach;

·    STAT-6 siRNA therapeutics targeting solid tumours with
significant in vivo efficacy; and

·    MK cell therapy with direct and NK cell-mediated anti-cancer action

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)
 and @RoquefortTherap on Twitter.

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK
MAR, provides further detail:

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Stephen West
 2   Reason for the notification
 a)  Position/status                                              Executive Chairman
 b)  Initial notification /Amendment                              Initial
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Roquefort Therapeutics plc
 b)  LEI                                                          254900P4SISIWOR9RH34
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.01 par value

     Identification code

                                                                  ISIN: GB00BMDQ2T15
 b)  Nature of the transaction                                    Purchase of 400,000 ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)                     Volume(s)
                                                                  2.57 pence per share         400,000
 d   Aggregated information

     - Aggregated volume                                          -       400,000

     - Price                                                      -       2.57p
 e)  Date of the transactions                                     4 February 2025
 f)  Place of the transactions                                    London Stock Exchange (XLON); Main Market

 

 

 

The notification below, made in accordance with the requirements of the UK
MAR, provides further detail:

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Ajan Reginald
 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification /Amendment                              Initial
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Roquefort Therapeutics plc
 b)  LEI                                                          254900P4SISIWOR9RH34
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.01 par value

     Identification code

                                                                  ISIN: GB00BMDQ2T15
 b)  Nature of the transaction                                    Trust distribution of 34,432 ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)                     Volume(s)
                                                                  2.6 pence per share          191,059
 d   Aggregated information

     - Aggregated volume                                          -       191,059

     - Price                                                      -       2.6p
 e)  Date of the transactions                                     4 February 2025
 f)  Place of the transactions                                    London Stock Exchange (XLON); Main Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBGGDDSUGDGUS